These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 7875155)

  • 21. Carboplatin in combination with epirubicin and cyclophosphamide in patients with advanced ovarian cancer. A phase II study.
    Andersson H; Friberg LG; Horvath G; Johansson O; Akesson M; Westberg R
    Acta Oncol; 1995; 34(6):821-7. PubMed ID: 7576751
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High-dose platinum chemotherapy in advanced ovarian cancer: a phase II study.
    Bertelsen K; Bastholt L
    Gynecol Oncol; 1992 Jan; 44(1):79-82. PubMed ID: 1730430
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group.
    Swenerton K; Jeffrey J; Stuart G; Roy M; Krepart G; Carmichael J; Drouin P; Stanimir R; O'Connell G; MacLean G
    J Clin Oncol; 1992 May; 10(5):718-26. PubMed ID: 1569444
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Results of a Southwest Oncology Group phase III trial of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide in advanced ovarian cancer.
    Hannigan EV; Green S; Alberts DS; O'Toole R; Surwit E
    Oncology; 1993 Nov; 50 Suppl 2():2-9. PubMed ID: 8233297
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dose escalation of paclitaxel with high-dose carboplatin using peripheral blood progenitor cell support in patients with advanced ovarian cancer.
    Fennelly DW; Aghajanian C; Shapiro F; O'Flaherty C; O'Connor K; Curtin JP; Crown JP; Hoskins WJ; Spriggs DR
    Semin Oncol; 1997 Feb; 24(1 Suppl 2):S2-26-S2-30. PubMed ID: 9045332
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of cyclophosphamide on relationships between carboplatin exposure and response or toxicity when used in the treatment of advanced ovarian cancer.
    Reyno LM; Egorin MJ; Canetta RM; Jodrell DI; Swenerton KD; Pater JL; Burroughs JN; Novak MJ; Sridhara R
    J Clin Oncol; 1993 Jun; 11(6):1156-64. PubMed ID: 8501502
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recombinant human interleukin-3 to dose-intensify carboplatin and cyclophosphamide chemotherapy in epithelial ovarian cancer: a phase I trial.
    Veldhuis GJ; Willemse PH; van Gameren MM; Aalders JG; Mulder NH; Mull B; Biesma B; de Vries EG
    J Clin Oncol; 1995 Mar; 13(3):733-40. PubMed ID: 7884433
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I/II study of the combination of carboplatin and paclitaxel as first-line chemotherapy in patients with advanced epithelial ovarian cancer.
    du Bois A; Lück HJ; Bauknecht T; Möbus V; Bochtler H; Diergarten K; Meerpohl HG
    Ann Oncol; 1997 Apr; 8(4):355-61. PubMed ID: 9209665
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase I/II study of PIXY321 in combination with cyclophosphamide and carboplatin in the treatment of ovarian cancer.
    Runowicz CD; Mandeli J; Speyer JL; Wadler S; Hochster H; Garrison L; Holland JF
    Am J Obstet Gynecol; 1996 Apr; 174(4):1151-9; discussion 1159-60. PubMed ID: 8623842
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomised trial investigating the dose intensity of primary chemotherapy in patients with ovarian carcinoma: a comparison of chemotherapy given every four weeks with the same chemotherapy given at three week intervals.
    Wrigley E; Weaver A; Jayson G; Ranson M; Renninson J; Prendiville J; Dobson M; Collins CD; Swindell R; Buckley CH; Radford JA; Crowther D
    Ann Oncol; 1996 Sep; 7(7):705-11. PubMed ID: 8905028
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dose-toxicity relationship of carboplatin in combination with cyclophosphamide in ovarian cancer patients.
    Sørensen BT; Strömgren A; Jakobsen P; Jakobsen A
    Cancer Chemother Pharmacol; 1991; 28(5):397-401. PubMed ID: 1914085
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High-dose chemotherapy with hematopoietic rescue in patients with stage III to IV ovarian cancer: long-term results.
    Legros M; Dauplat J; Fleury J; Cure H; Suzanne F; Chassagne J; Bay JO; Sol C; Canis M; Condat P; Choufi B; Tavernier F; Glenat C; Chollet P; Plagne R
    J Clin Oncol; 1997 Apr; 15(4):1302-8. PubMed ID: 9193321
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ICON 2 and ICON 3 data in previously untreated ovarian cancer: results to date.
    Harper P
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-23-S15-25. PubMed ID: 9346217
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cisplatin, carboplatin, and cyclophosphamide combination chemotherapy in advanced-stage ovarian carcinoma: an Eastern Cooperative Oncology Group pilot study.
    Grem J; O'Dwyer P; Elson P; Simon N; Trump D; Frontiera M; Falkson G; Vogl S
    J Clin Oncol; 1991 Oct; 9(10):1793-800. PubMed ID: 1919629
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Paclitaxel by 1-h infusion in combination with carboplatin in advanced non-small cell lung carcinoma (NSCLC).
    Langer CJ; McAleer CA; Bonjo CA; Litwin S; Millenson M; Kosierowski R; Blankstein K; Alexander R; Ozols RF
    Eur J Cancer; 2000 Jan; 36(2):183-93. PubMed ID: 10741276
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dose intensive combination platinum and cyclophosphamide in the treatment of patients with advanced untreated epithelial ovarian cancer.
    Shapiro JD; Rothenberg ML; Sarosy GA; Steinberg SM; Adamo DO; Reed E; Ozols RF; Kohn EC
    Cancer; 1998 Nov; 83(9):1980-8. PubMed ID: 9806657
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pilot study of cyclophosphamide plus carboplatin in advanced ovarian carcinoma.
    Edmonson JH; McCormack GW; Krook JE; Long HJ; Jefferies JA; Richardson RL
    Cancer Treat Rep; 1987 Feb; 71(2):199-200. PubMed ID: 3542210
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase I trial of carboplatin-cyclophosphamide and iproplatin-cyclophosphamide in advanced ovarian cancer: a Southwest Oncology Group study.
    Alberts D; Mason N; Surwit E; Weiner S; Hammond N; Deppe G
    Cancer Treat Rev; 1985 Sep; 12 Suppl A():83-92. PubMed ID: 3910225
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Carboplatin alone compared with its combination with epirubicin and cyclophosphamide in untreated advanced epithelial ovarian cancer: a Hellenic co-operative oncology group study.
    Skarlos DV; Aravantinos G; Kosmidis P; Pavlidis N; Gennatas K; Beer M; Mylonakis N; Makrantonakis P; Klouvas G; Karpathios S; Linardou H; Konstantaras C; Fountzilas G
    Eur J Cancer; 1996 Mar; 32A(3):421-8. PubMed ID: 8814685
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of peripheral-blood progenitor cells abrogates the myelotoxicity of repetitive outpatient high-dose carboplatin and cyclophosphamide chemotherapy.
    Tepler I; Cannistra SA; Frei E; Gonin R; Anderson KC; Demetri G; Niloff J; Goodman H; Muntz H; Muto M
    J Clin Oncol; 1993 Aug; 11(8):1583-91. PubMed ID: 8101563
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.